BMS-986525
/ BMS
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 09, 2026
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
(clinicaltrials.gov)
- P1/2 | N=240 | Recruiting | Sponsor: Bristol-Myers Squibb | Initiation date: Feb 2025 ➔ Feb 2026
Monotherapy • Trial initiation date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
February 20, 2026
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
(clinicaltrials.gov)
- P1/2 | N=240 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting | Initiation date: Feb 2026 ➔ Feb 2025
Enrollment open • Monotherapy • Trial initiation date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
January 09, 2026
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
(clinicaltrials.gov)
- P1/2 | N=240 | Not yet recruiting | Sponsor: Bristol-Myers Squibb
Monotherapy • New P1/2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
1 to 3
Of
3
Go to page
1